Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares. The shares were sold on July 1, 2026 at a weighted average price of $55.8802 per share in multiple trades within a disclosed price range. The filing states that all reported transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. After this sale, Urist reports no directly held Class A shares and an indirect holding of 19,020 shares through an IRA.
Royalty Pharma plc executive Christopher Hite reported pre-planned open-market sales of 130,000 Class A Ordinary Shares on June 30, 2026 under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices generally between about $56 and $57 per share.
After these transactions, Hite holds 40,000 Class A Ordinary Shares directly. Additional shares are held indirectly through SCH Investment Partners LLC, which reported post-transaction ownership of 461,953 Class A Ordinary Shares. Some of the sales in this filing were executed by that LLC rather than by Hite personally.
Royalty Pharma plc reported proposed dispositions of Common Stock by Marshall Urist. The filing lists three sale notices: 13,684 shares on 05/14/2026 valued at $726,137.82, 13,684 shares on 05/20/2026 valued at $721,837.21, and 9,098 shares on 06/24/2026 valued at $502,066.55.
The notice also shows an Equity Performance Award of 9,099 Class A Ordinary Shares granted on 05/08/2026 as part of the issuer's equity compensation program. The filing records these transactions as notices of sale under Form 144.
Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Bonnie L. Bassler received an award of 689 Class A Ordinary Shares, valued at $54.3998 per share. The shares were issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a quarterly cash retainer of $37,500.
After this equity award, Bassler directly holds 79,181 Class A Ordinary Shares. This transaction reflects compensation paid in stock rather than cash, and does not represent an open-market purchase or sale.
Royalty Pharma plc EVP Marshall Urist reported an open-market sale of 9,098 Class A Ordinary Shares of RPRX at a weighted average price of $55.1843 per share. After this transaction, he directly holds 9,099 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, meaning the trades were scheduled in advance rather than timed discretionarily.
Royalty Pharma plc executive Christopher Hite reported pre-planned insider sales linked to an affiliated entity. On June 23, 2026, SCH Investment Partners LLC, an entity associated with Hite, sold a total of 150,000 Class A Ordinary Shares in open-market transactions at weighted average prices of $54.47 and $54.11 per share.
All transactions were executed under a Rule 10b5-1 trading plan adopted on March 20, 2026, indicating they were scheduled in advance. Following these sales, SCH Investment Partners LLC held 676,991 Class A Ordinary Shares indirectly for Hite, while he also held 70,000 shares directly.
Royalty Pharma plc (RPRX) reported reported Form 144 activity showing insider transactions by Marshall Urist. The filing lists sales of 13,684 shares on 05/14/2026 for $726,137.82 and 13,684 shares on 05/20/2026 for $721,837.21. The excerpt also shows a 9,098-share Equity Performance Award granted on 05/08/2026.